Medical Weight Loss: The Complete Clinical Guide

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·18 min read

Medical weight loss is physician-supervised weight management built on a simple but powerful premise: obesity is a chronic, relapsing, multifactorial disease, and it deserves to be treated like one. Rather than handing a patient a diet sheet and hoping for the best, a medical weight loss practice assesses the whole person — body composition, labs, comorbidities, hormones, behavior — and then builds an individualized plan that may combine nutrition, structured behavior change, FDA-approved and off-label medications, injectable adjuncts, and ongoing monitoring. This pillar guide is the single, honest reference for understanding that whole landscape, then going deeper through the individual guides linked throughout.

Because weight management is a Your-Money-or-Your-Life medical topic, accuracy matters. Throughout this guide we distinguish carefully between what is FDA-approved, what is off-label, and what is genuinely investigational or unproven, and we hedge efficacy claims accordingly. The science of weight loss is a constantly changing field, with new agents and data arriving continually; responsible practice means staying current rather than relying on what was true a year ago. Nothing here is medical advice — it is clinical education for providers and an orientation for patients deciding whether to ask their physician about a medical program.

What is medical weight loss?

The defining feature of medical weight loss is medical oversight. A licensed clinician evaluates the patient, identifies the contributors to their weight, selects and prescribes treatment, and monitors for both effect and safety over time. That is what separates it from the commercial weight loss industry — a market projected to approach $295 billion by 2027 — where do-it-yourself programs and fad protocols dominate. The average adult will try roughly 126 different diets in a lifetime, and most fail not because the patient lacked discipline but because the underlying physiology was never addressed.

A medical program starts from a different place. It recognizes that weight is governed by a network of hormones, neurotransmitters, and signaling pathways linking the gut, pancreas, adipose tissue, and brain — leptin (the satiety hormone from fat cells), ghrelin (the hunger hormone from an empty stomach), insulin, cortisol, and more. During weight loss, ghrelin rises and leptin falls, which is precisely why the body fights to regain lost weight and why a serious program plans for maintenance from day one. Setting realistic goals and long-term maintenance plans is part of the clinical work, not an afterthought.

Medical weight loss is also a fast-growing, predominantly cash-pay service line, which is why so many practices are adding it. But it is regulated medicine. Prescribing weight-loss controlled substances requires a current DEA registration, awareness of state-specific rules, and thorough documentation — including a comprehensive physical exam and a clearly stated weight-loss goal in the chart. Some states even define nutrition counseling as within the scope of a registered dietitian, so clinicians should verify their state board and malpractice carrier before building a program.

Obesity as a chronic, multifactorial disease

The most important reframe in this entire field is the one that opens Dr. Greenleaf's course: obesity is a medical diagnosis, not a moral judgment. Formally, it is a chronic, relapsing, multifactorial neurobehavioral disease in which an increase in body fat promotes adipose tissue dysfunction and abnormal fat-mass physical forces, producing adverse metabolic, biomechanical, and psychosocial health consequences. Adipose tissue is not inert storage — it is an active endocrine organ that secretes leptin and other signals, and when it becomes dysfunctional, the downstream effects ripple across nearly every organ system.

The scale of the problem explains why this matters clinically. More than one in three adults and one in five children struggle with obesity, and rates have risen steadily since the 1970s. Obesity raises the risk of heart disease, type 2 diabetes, fatty liver, and certain cancers, and it costs the U.S. health system on the order of $173 billion a year. The Framingham Heart Study quantified the stakes starkly: a measurable increase in risk of death over the following decades for every extra pound gained in early adulthood, and even a five-pound gain raised the risk of developing fatty liver disease.

Crucially, obesity is not a simple energy-in, energy-out equation. Long-term positive energy balance is a contributor, but so are genetics, sleep, stress, medications, hormones, the gut microbiome, and the environment — and 260 calories of one food does not act on the body the same way as 260 calories of another. Understanding obesity as a multifactorial disease is what licenses the clinician to treat it with the full range of medical tools rather than blaming the patient. We unpack the pathophysiology, the hormonal drivers, and the evidence in depth in the dedicated guide on obesity as a disease.

Patient assessment: BMI, body composition, labs & comorbidities

Good medical weight loss begins with measurement, because what we can quantify, we can track and follow. The foundational metric is BMI — weight in kilograms divided by height in meters squared — with overweight defined as 25 to 29.9 and obesity as 30 or higher. BMI is cheap, standardized, and strongly correlated with body fat at the population level, which is why it remains the entry point. But its limitations are real and must be taught: it does not distinguish lean mass from fat mass (a muscular athlete and a sedentary person of the same height can share a BMI), and it is less accurate in the elderly and varies by sex and ethnicity.

That is why a thorough assessment looks beyond BMI to body composition and fat distribution. Simple, inexpensive measures include waist circumference and the waist-to-hip ratio, both of which predict disease and mortality and capture the abdominal fat that BMI misses. More precise research-grade methods — air-displacement plethysmography (the Bod Pod), DXA, hydrostatic weighing, and CT/MRI — offer greater accuracy at greater cost, and several become unreliable above a BMI of 35.

The assessment also includes labs and a comorbidity review. Clinicians evaluate metabolic markers and screen for the conditions that both drive and complicate obesity — insulin resistance and type 2 diabetes, dyslipidemia, hypertension, fatty liver, PCOS, thyroid dysfunction, sleep apnea, and the hormonal contributors that shape appetite and energy balance. This workup is what makes treatment selection rational: a patient with insulin resistance, a patient with reward-based eating, and a patient with a cardiac history are not candidates for the same first-line agent.

The pharmacologic toolbox

Medication is one tool in a comprehensive program, never a standalone cure, and certain patients are excluded from pharmacologic treatment altogether — pregnancy, unstable cardiac disease, uncontrolled hypertension, severe systemic illness, unstable psychiatric history, a history of anorexia, and incompatible medications such as MAO inhibitors. Within those guardrails, the modern toolbox spans several mechanisms. Here is the orientation; each agent has its own deep-dive guide, and the specific dosing and titration schedules stay in Empire's training.

Phentermine

The most commonly prescribed appetite suppressant. Phentermine increases brain norepinephrine, serotonin, and dopamine to suppress appetite and modestly raise energy expenditure, with average weight loss of roughly 3% of body weight at three months and 5–7% at six months. It is a scheduled controlled substance, generally indicated for short-term use, and works better in combination than alone. See the full phentermine guide.

Phentermine-topiramate

An FDA-approved combination that pairs phentermine's appetite suppression with topiramate, which adds further appetite reduction through a mechanism that is not fully understood. The combination typically produces greater weight loss than phentermine alone, but topiramate carries cognitive and mood considerations and a potential for birth defects, so candidate selection matters. See the phentermine-topiramate guide.

Naltrexone-bupropion

An FDA-approved combination that works synergistically: bupropion influences the brain's appetite-regulation centers, while naltrexone, an opioid antagonist, acts on reward pathways — making it particularly useful for reward-based or emotional eating. It carries bupropion's black-box warning about suicidal behavior in psychiatric patients and is not a standalone solution. See the naltrexone-bupropion guide.

Metformin

Around since the 1950s and originally a diabetes and PCOS drug, metformin works on insulin resistance and can promote modest weight loss by reducing appetite, altering the gut microbiota, and influencing appetite-regulating brain regions. It is not FDA-approved as a standalone weight-loss drug but is commonly used off-label, especially in patients with diabetes or prediabetes.

Orlistat

FDA-approved in 1997, orlistat is a lipase inhibitor that blocks the breakdown and absorption of dietary fat in the gut, leading to fecal excretion of undigested fat. It is available by prescription and over the counter, and its mechanism predicts its tolerability challenges around dietary fat intake.

GLP-1 and GLP-1/GIP receptor agonists

The most effective pharmacologic agents available today. Semaglutide, dosed weekly, has been associated with up to roughly 16% weight loss over placebo, and the dual GIP/GLP-1 agonist tirzepatide has demonstrated dose-dependent weight loss reaching the high teens to about 21% in trials. Both mimic gut hormones to reduce appetite, enhance insulin response, and slow gastric emptying. They carry meaningful contraindications — a personal or family history of medullary thyroid carcinoma or MEN-2, caution around pancreatitis and gastroparesis, and pregnancy — and demand monitoring. Start with the overview in the GLP-1 medications guide, and for molecule-level detail see the peptide-cluster guides on semaglutide and tirzepatide. For the full landscape, see weight-loss medications.

Medical weight loss guides

Below is a map of the clinical topics patients and providers ask about most. We are publishing in-depth, evidence-reviewed guides for each one — the directory will fill in over the coming weeks as new guides go live.

Injectable adjuncts: MIC/lipotropic, HCG & B12

Beyond the prescription medications, many medical weight loss practices offer injectable adjuncts — supportive injections positioned alongside, not instead of, the core plan. The most common are MIC/lipotropic injections, blends built around lipotropic compounds (classically methionine, inositol, and choline) often combined with B vitamins. They are marketed to support fat metabolism and energy, and they are best understood as adjuncts whose evidence is modest and whose value is partly in patient engagement and adherence. The full clinical picture, formulations, and honest evidence review live in the MIC/lipotropic injections guide.

Vitamin B12 injections are frequently bundled into weight-loss programs for energy support and to address deficiency, particularly relevant given the deficiencies that some restrictive diets and certain medications can produce. As with lipotropics, B12 is a supportive measure rather than a weight-loss agent in its own right, and it should be framed that way honestly with patients.

HCG (human chorionic gonadotropin) deserves a clear-eyed treatment. The "HCG diet" pairs HCG with an extremely low-calorie regimen, and any rapid weight loss seen is driven by severe caloric restriction — with a likely placebo component — rather than by HCG itself. Very-low-calorie protocols carry real risks, including muscle loss, gallstones, electrolyte disturbance, and mood effects, and they are not sustainable. Providers should understand the history, the regulatory status, and the limited evidence before offering it; we cover that candidly in the HCG for weight loss guide.

Nutrition & lifestyle foundation

No medication works without a foundation under it, and that foundation is nutrition, activity, behavior, and sleep. Dr. Greenleaf's course surveys the major dietary approaches honestly — each with advantages and drawbacks. The Mediterranean diet is widely favored as a maintenance pattern after weight loss. Low-glycemic eating reduces the glucose and insulin response and is a practical, sustainable lever. Higher-protein diets are more satiating and, in randomized comparisons, tend to produce more weight loss with somewhat better preservation of lean mass than high-carbohydrate, low-fat diets. Ketogenic and intermittent fasting approaches can work for the right patient but carry specific cautions and contraindications, especially in diabetes. The clinical art is matching the pattern to the patient rather than evangelizing one diet for everyone.

Exercise plays an essential but frequently misunderstood role. The CDC recommends at least 150 minutes a week of moderate aerobic activity plus strength training twice weekly, and physical activity independently improves cardiovascular and metabolic health and helps preserve lean mass during weight loss. But a key teaching point pushes back on the popular myth: you cannot out-exercise a bad diet, and exercise alone produces little additional weight loss. Worse, excessive or overly strenuous exercise can halt weight loss by activating stress hormones — the body cannot distinguish deliberate overtraining from famine or injury, so it holds onto weight. Moderate activity with adequate protein, not punishing workouts, is the right prescription during active weight loss.

Behavior and self-monitoring tie it together. Food, activity, and sleep tracking — through apps, wearables, and even continuous glucose monitors — let patients quantify and adjust their behavior, and the act of tracking itself reinforces change. Sleep is its own lever: poor sleep lowers growth hormone and leptin while raising cortisol, insulin, and ghrelin, a hormonal recipe for weight-loss resistance. A program that ignores sleep and behavior is treating only half the disease.

The GLP-1 era and where it fits

It is impossible to discuss medical weight loss in 2026 without addressing the GLP-1 era. GLP-1 (glucagon-like peptide-1) is a hormone produced in the intestines and brainstem after eating; it stimulates insulin release, suppresses glucagon, slows gastric emptying, and acts on the hypothalamus and brainstem to decrease appetite and increase fullness. GLP-1 receptor agonists mimic that natural signal with a much longer duration of action, and the dual GIP/GLP-1 agonist tirzepatide adds a second incretin mechanism. The result is the most effective pharmacotherapy the field has ever had — semaglutide associated with up to about 16% weight loss over placebo, tirzepatide reaching the high teens to roughly 21% at higher doses. These agents are why peptide-based weight loss has gone mainstream, and they connect this cluster directly to the broader peptide therapy landscape; for the agent-level deep dives, see semaglutide, tirzepatide, and the dual/triple agonists like retatrutide and the broader peptides for weight loss overview.

But the GLP-1 era brings a clinical caveat that providers must own: weight loss on these agents is systemic, not targeted, and rapid loss includes lean mass, not just fat — the phenomenon behind colloquial terms like "Ozempic face." Preserving lean mass is therefore central to using these drugs well: adequate protein intake, resistance training, and appropriate titration matter as much as the prescription itself. The lesson from the exercise physiology above applies directly here — the goal is to lose fat while protecting muscle, and a GLP-1 prescribed without a lean-mass strategy is an incomplete plan.

The honest framing is that GLP-1s are a transformative tool, not a replacement for the program. Many patients are not candidates because of contraindications, cost, tolerability, or access, and these agents should sit inside a comprehensive lifestyle intervention with monitoring rather than be handed out in isolation. Which is exactly why you do not need a GLP-1 to run a credible medical weight loss practice — you need the whole toolbox.

Safety, monitoring & realistic expectations

Safety in medical weight loss rests on three things: correct patient selection, appropriate monitoring, and honest expectations. Selection means respecting the contraindications — the GLP-1 thyroid and pancreatitis cautions, phentermine's cardiovascular and psychiatric exclusions, topiramate's cognitive and teratogenic risks, bupropion's black-box warning — and screening every patient before, not after, prescribing. The same rigor applies to very-low-calorie and fad protocols, which carry their own meaningful risks.

Monitoring is continuous. Controlled-substance prescribing demands a documented physical exam, a charted weight-loss goal, accurate dispensing logs, and adherence to state limits on duration — some states cap weight-loss medication courses, and at least one prohibits certain scheduled drugs for weight loss entirely. Beyond compliance, clinical monitoring tracks response, tolerability, and adverse effects, and knows when to pause or change course. This is medicine, not retail.

Realistic expectations are a clinical intervention in their own right. The natural history of weight is to creep upward with age as metabolism shifts and muscle declines, and the body actively defends against weight loss through rising ghrelin and falling leptin. Patients should understand that maintenance is the hard part, that results plateau, and that "quicker at first" rarely means "more in the end." Setting those expectations honestly — and planning for long-term maintenance from the start — is what makes a program durable rather than a revolving door.

Building a medical weight loss practice

For providers, medical weight loss is one of the most accessible and in-demand cash-pay service lines in functional and aesthetic medicine — the weight-loss market is enormous and growing, and demand for physician-supervised programs has only accelerated in the GLP-1 era. But building it responsibly means treating it as a clinical service, not a retail product.

The operational backbone includes the right regulatory footing — a current DEA registration permitting Schedule III and IV prescribing, knowledge of state-specific rules, childproof containers, clear labeling, and meticulous records of who received what, when, and how much. It means sourcing only from reputable U.S. distributors, keeping all shipment paperwork for stocked controlled substances, and never filling a prescription without a documented patient encounter in the chart. And if the practice sells supplements, it means the correct FDA disclaimer language on the website and an honest stance on what supplements can and cannot do.

Beyond compliance, a durable program is built on systems: a repeatable assessment workflow, defined treatment pathways for different patient profiles, structured follow-up and monitoring, behavior-change support, and clear maintenance protocols. That combination — clinical rigor plus operational structure — is what turns medical weight loss into a sustainable, defensible, and profitable part of a practice rather than a liability.

How providers get trained

Licensed physicians, nurse practitioners, physician assistants, and nurses can all add medical weight loss to their scope with appropriate clinical training. A strong program goes far beyond a medication list — it teaches the science of obesity, the assessment and monitoring workflow, the full medication and injectable toolbox with its dosing and contraindications, the nutrition and behavior foundation, and the regulatory and operational realities of running the service safely and compliantly. Empire's Physician Medical Weight Loss Training is structured exactly this way and sits within the broader Academy of Anti-Aging & Functional Medicine, alongside hormone replacement, peptide therapy, and IV nutrient therapy. To go deeper on individual topics, explore the guides in the directory above or return to the Resource Center as new guides publish.